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Novel EGFR V834L Germline 
Mutation Associated With Familial 
Lung Adenocarcinoma
INTRODUCTION
Lung cancer is a worldwide, known disease with 
a high mortality rate and is often related to nico-
tine abuse. Family-related lung cancer has been 
reported occasionally, but little is known about 
the genetic backgrounds. With routine analysis 
for targetable mutations, unexpected potentially 
pathogenic mutations may be found. Here, we 
present a case study of a patient with a target-
able somatic EGFR mutation and a novel EGFR 
germline variant, which also occurred in other 
family members with lung cancer.
INDEX PATIENT
Our female index patient of Surinam origin, 
a former smoker with a 10 pack-year history, 
was diagnosed at the age of 57 years with non–
small-cell lung cancer (NSCLC), stage IIIA 
cT2bN2M0 adenocarcinoma. Initial treatment 
included concurrent chemotherapy and radio-
therapy, and palliative chemotherapy after 
recurrence (the treatment timeline is shown in 
Fig 1). After a second recurrence, a new biopsy 
of a lymph node metastasis was obtained for 
EGFR mutation analysis by next-generation 
sequencing. This analysis revealed a well-known 
oncogenic L858R mutation along with a V834L 
variant, which are both EGFR exon 21 substitu-
tions and are present in the same allele (in cis). 
The V834L variant seemed to be present in the 
germline, because both normal adjacent lymph 
node tissue and lymphocyte-derived DNA from 
whole blood of the index patient showed this 
variant.
The patient was treated with the EGFR tyro-
sine kinase inhibitor (TKI) erlotinib. At the 
fourth progression of the disease, the patient 
was retreated with chemotherapy. After the 
fifth progression of the disease, a new biopsy 
revealed a first-generation TKI-resistance EGFR 
T790M mutation, in addition to L858R and 
V834L. Therefore, treatment was switched to 
the third-generation EGFR TKI osimertinib. 
Because of progression after 1 year of osimerti-
nib treatment, a liquid biopsy was taken and cell-
free DNA was isolated. Subsequent mutation 
analysis showed that the progression was prob-
ably because of the development of EGFR resis-
tance mutation C797S in cis with T790M (data 
not shown). Performance of the patient was 
declining, and there were no remaining thera-
peutic options. Best supportive care was given, 
and the patient eventually died.
PATIENT’S FAMILY HISTORY WAS 
POSITIVE FOR LUNG CANCER
The patient’s younger brother, who was 57 years 
old and a current smoker, was diagnosed in 2016 
with stage IV, EGFR L858R mutation–positive 
NSCLC. He was treated with erlotinib, and his 
disease progressed after 3 months. A new biopsy 
was obtained, revealing no targetable secondary 
resistance mechanism, such as T790M mutation 
or MET amplification. Standard chemotherapy 
was started, but the patient died because of dis-
ease progression and decline in performance 
status.
A sister and daughter of our index patient, 46 
and 42 years old, respectively, both nonsmokers, 
were diagnosed with stage IV NSCLC before 
the knowledge and treatment options of EGFR 
mutations. They were both treated with pallia-
tive chemotherapy but died as a result of disease 
progression. The patient’s father died at a young 
age as the result of massive hemoptysis, without 
a diagnosis.
After written consent and permission were 
obtained from the index patient and family 
members, EGFR mutation and germline vari-
ation analyses were performed on tumor sam-
ples and healthy tissue, respectively, of the three 
affected relatives. Because our study started after 
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the deaths of the index patient’s brother, sister, 
and daughter, no blood was available; only archi-
val formalin-fixed paraffin-embedded normal 
and tumor tissues were available.
Like our index patient, all three affected fam-
ily members had a heterozygous EGFR V834L 
germline variant in normal tissue and the same 
somatic EGFR L858R mutation in cis with the 
V834L variant in their respective tumor tissues. 
No tissue samples from the patient’s father were 
available.
Further germline research was performed in 
four healthy family members who did not have 
signs of lung cancer. One of the index patient’s 
children, who was 36 years old, showed the same 
heterozygous EGFR V834L germline variant. 
All other investigated family members were wild 
type at this position in EGFR (Fig 2).
DISCUSSION
Little is known about hereditary lung cancer. 
This is probably in part because lung cancer is 
strongly associated with smoking and therefore a 
familial association may be easily missed. To our 
knowledge, this is the first report of a family 
with multiple cases of NSCLC associated with 
germline transmission of an EGFR V834L 
germline variant; all tumors in the four family 
members additionally harbored a somatic EGFR 
L858R mutation in cis. All except one of the known 
V834L carriers developed lung cancer during 
their lifespan, but so far none of the investigated 
noncarriers.
There are only a few reports documenting 
families with proven inherited EGFR variants 
over generations that probably conferred pre-
disposition to lung cancer.1,2 In a family with 
EGFR V843I mutations, four family members 
in two generations (three of them with proven 
germline variants) developed lung adenocarci-
noma.1 As in the family we studied, all of these 
adenocarcinomas displayed a somatically-acquired 
L858R mutation in cis with V843I. The index 
patient in the family with EGFR V843I muta-
tions was treated with erlotinib and gefitinib, 
but without response, even though the L858R 
mutation was present. Also, in vitro, the V843I 
substitution conferred TKI resistance. Yu et al2 
described a family carrying a germline T790M 
mutation. In their study, both the index patient 
and her mother developed lung adenocarcino-
mas. Interestingly, multiple distinct synchronous 
tumors of the index patient displayed different 
additional EGFR mutations (ie, deletions of 3 
and 15 bp in exon 19 and L858R).2 A report by 
Bell et al3 describes a family with five members 
affected by lung cancer. Proven germline EGFR 
T790M mutations were present in three patients 
in two generations.3 In distinct lesions in two of 
these patients, the mutation co-occurred with 
different EGFR substitutions (L858R, L747-
T751del, and G716A), all in cis with T790M. 
Because T790M is a well-known TKI resistance 
mutation, no response was observed upon gefi-
tinib treatment in the only TKI-treated patient 
of this family, as expected.
Incidental cases of germline EGFR variants in 
patients with lung cancer have been reported. 
These have included variants such as V769M, 
R776H, and T790M substitutions in exon 20 
and R831C, V843I, and P848L substitutions 
in exon 21.4-9 However, in the absence of fam-
ily histories, it is unclear whether these vari-
ants predisposed these patients to lung cancer. 
Importantly, as described above, these germline 
variants often co-occur in the tumor with other, 
mostly well-known, actionable EGFR mutations. 
This strongly indicates that somatically acquired 
secondary EGFR mutations are indispensable for 
tumorigenesis.
We hypothesize that presence of the EGFR 
V834L germline variant is causative for the high 
incidence and early onset of lung cancer in the 















Fig 1. Timeline of 
treatment and detection of 
acquired somatic EGFR mu-
tations of the index patient. 
The germline EGFR variant 
V834L is indicated at all 
time points. 
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family we studied. So far, all lung cancers in 
this family have been found to harbor both the 
EGFR V834L variant and the well-described 
oncogenic EGFR L858R mutation. Although this 
is a relatively small cohort, this may indicate 
that the V834L variant is not or only weakly 
oncogenic and by itself is not sufficient to drive 
uncontrolled growth. However, when a second 
oncogenic mutation in cis is present, cell growth 
accelerates more than proportionally.
This hypothesis is in line with eight described 
EGFR V834L variants found in the Catalogue 
Of Somatic Mutations In Cancer database.9 
The V834L variant in the lung tumors of all of 
these patients, with unknown germline status, 
is accompanied by the L858R mutation (seven 
times) or by an exon 19 deletion.10-12 The rea-
son for the apparent preference of V834L for 
L858R is unclear. Such a preference is not 
unique (eg, the germline variant EGFR V769M 
preferentially associates with mutations of codon 
G719 and/or S768). This is possibly because the 
energy balance of the EGFR V769M–substituted 
protein does not favor combination with L858R.9 
Structural and functional analysis of the V834L 
variant alone and/or in combination with strong 
oncogenic driver mutations can provide additional 
mechanistic information on its pathogenicity 
and preferred association with other oncogenic 
EGFR mutations.
Until now, lung cancer surveillance programs 
have been mainly recommended for active smok-
ers or patients with a smoking history of 30 pack- 
years but who have stopped within the last 
15 years. Although smoking is unmistakably asso-
ciated with lung cancer development, increased 
awareness of genetic factors that predispose indi-
viduals to lung cancer is necessary. Currently, the 
prevalence of germline EGFR T790M mutations 
in patients with lung cancer and their relatives 
is being studied in the INHERIT EGFR trial 
(NCT01754025), to further investigate the role 
of EGFR mutations in lung cancer development. 
For people with a germline EGFR mutation and/
or a strong family history of lung cancer, clinical 
follow-up may be recommended.
In conclusion, we describe a novel EGFR V834L 
germline mutation illustrating that genetic fac-
tors may play an important role in lung cancer 
predisposition and should be evaluated to opti-
mize surveillance and clinical genetic counseling.
DOI: https://doi.org/10.1200/PO.17.00266 
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2018.



















Fig 2. Pedigree of a 
family with non–small-cell 
lung cancer (NSCLC) asso-
ciated with the presence of 
an EGFR V834L germline 
variant. Squares and circles 
represent male and female 
family members, respec-
tively. Diagonal strikes 
represent deceased family 
members. Age at diagnosis 
of the indicated cancer or at 
death (d) is indicated below 
the squares and circles. 
LuC, lung cancer; PrC, 
prostate cancer; yo, years 
old.
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